- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.12.25 | ProKidney Corp. (PROK) Positioned to Redefine Chronic Kidney Disease Treatment, Believes H.C. Wainwright | 2 | Insider Monkey | ||
| 16.12.25 | ProKidney: H.C. Wainwright stuft Aktie mit "Kaufen" ein und sieht Kurspotenzial von über 475 % | 3 | Investing.com Deutsch | ||
| 16.12.25 | H.C. Wainwright initiates ProKidney stock with Buy rating, $12 target | 2 | Investing.com | ||
| 11.11.25 | PROKIDNEY CORP. Q3 Loss Decreases, Beats Estimates | 1 | RTTNews | ||
| 10.11.25 | ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates | 168 | GlobeNewswire (Europe) | Full results from the Phase 2 REGEN-007 study of rilparencel were recently presented as a late-breaking clinical trial at the American Society of Nephrology (ASN) Kidney Week 2025More than half of... ► Artikel lesen | |
| PROKIDNEY Aktie jetzt für 0€ handeln | |||||
| 10.11.25 | PROKIDNEY CORP. - 8-K, Current Report | - | SEC Filings | ||
| 10.11.25 | PROKIDNEY CORP. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 06.11.25 | ProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025 | 341 | GlobeNewswire (Europe) | In patients with advanced chronic kidney disease (CKD) and diabetes, treatment with rilparencel resulted in statistically significant and clinically meaningful slowing of CKD progressionBilateral... ► Artikel lesen | |
| 20.10.25 | ProKidney Announces Two Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2025 | 1 | GlobeNewswire (USA) | ||
| 17.10.25 | PROKIDNEY CORP. - 8-K, Current Report | 1 | SEC Filings | ||
| 22.09.25 | ProKidney: Hoffnung für Patienten, Chance für Investoren | 398 | sharedeals.de | Die Forschung im Bereich der Nierenerkrankungen entwickelt sich rasant, und neue Therapieansätze rücken in den Fokus von Investoren und Fachwelt. Besonders spannend ist die Frage, ob ProKidney mit seiner... ► Artikel lesen | |
| 20.09.25 | ProKidney Corp (PROK) Touts Reparencel Therapy for Growth | 1 | Insider Monkey | ||
| 08.09.25 | ProKidney auf Morgan-Stanley-Konferenz: Strategische Einblicke in die Therapie chronischer Nierenerkrankungen | 3 | Investing.com Deutsch | ||
| 12.08.25 | PROKIDNEY CORP. - 8-K, Current Report | 3 | SEC Filings | ||
| 12.08.25 | PROKIDNEY CORP. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.08.25 | ProKidney Reports Second Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates | 316 | GlobeNewswire (Europe) | FDA confirmed at a July 2025 Type B meeting and in the subsequent meeting minutes that eGFR slope is an acceptable surrogate endpoint for accelerated approval of rilparencel in patients with type... ► Artikel lesen | |
| 16.07.25 | ProKidney schließt Sitzverlegung nach Delaware ab und strukturiert Verträge neu | 5 | Investing.com Deutsch | ||
| 15.07.25 | ProKidney stock soars after FDA confirms accelerated approval pathway | 2 | Investing.com | ||
| 15.07.25 | ProKidney, FDA align on accelerated approval pathway for Rilparencel | 1 | Seeking Alpha | ||
| 15.07.25 | ProKidney Secures FDA Alignment On Accelerated Approval Pathway For Rilparencel | 1 | RTTNews |
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 84,60 | -1,34 % | BYD gegen Tesla! KI-Profiteure BioNTech und Rio Tinto Partner Aspermont! Aktien für 2026? | Paukenschlag kurz vor Silvester! BYD hat Tesla vom E-Auto-Thron gestoßen. Die Chinesen sind jetzt auch Weltmarktführer bei rein elektrischen Fahrzeugen. Doch die Aktie hat 2025 klar enttäuscht. Ein... ► Artikel lesen | |
| QIAGEN | 41,290 | 0,00 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 07.01.2026 | Das Instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON EQUITY wird cum Kapitalmassnahme gehandelt am 07.01.2026 und ex Kapitalmassnahme am 08.01.2026 The instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON... ► Artikel lesen | |
| VALNEVA | 4,198 | +0,67 % | EILMELDUNG: Valneva-Aktie zieht durch - kommt jetzt die große Rallye? | ||
| NOVAVAX | 6,310 | -3,22 % | Novavax, Inc.: Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights | Total revenue of $70 million in the third quarter of 2025
Continued successful execution of Sanofi partnership with $225 million in milestones achieved year-to-date... ► Artikel lesen | |
| STRYKER | 315,40 | +0,22 % | VB Spine LLC: VB Spine Completes Acquisition of Cestas Manufacturing Facility from Stryker | Deal expands global manufacturing footprint and positions VB Spine for future growth in spine care VB Spine LLC ("VB Spine") today completed the acquisition of Stryker's spine implant manufacturing... ► Artikel lesen | |
| HEIDELBERG PHARMA | 2,980 | +0,34 % | HEIDELBERG PHARMA AG zeigt fundamentale Stärke | ||
| VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Labs Appoints Amar Sethi, M.D., Ph.D. as Chief Scientific Officer | SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim Labs"), a pharmaceutical and biotechnology services company that is focused on providing testing... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,400 | -2,78 % | INOVIO Pharmaceuticals, Inc.: FDA Accepts for Review INOVIO's BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP) | PLYMOUTH MEETING, Pa., Dec. 29, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help... ► Artikel lesen | |
| OCUGEN | 1,290 | -5,56 % | Ocugen Provides Business Update with Third Quarter 2025 Financial Results | Phase 2/3 OCU410ST GARDian3 pivotal confirmatory trial is progressing toward 1H 2027 Biologics License Application (BLA) filing with 50% enrollment completed to date European Medicines Agency (EMA)... ► Artikel lesen | |
| MAINZ BIOMED | 1,175 | 0,00 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed gibt Rückblick auf die Highlights des Jahres 2025 | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Sonstiges
Mainz Biomed gibt Rückblick auf die Highlights des Jahres 2025
05.01.2026 / 14:15 CET/CEST
Für den... ► Artikel lesen | |
| INFLARX | 0,950 | -7,95 % | Weekly Buzz: ARS Pharma's Neffy Goes East, SLS Advances, A Signal Of Hope For IFRX? | LONDON (dpa-AFX) - Despite the typical year-end slowdown, the week saw a steady stream of high-impact news, highlighted by global approvals, clinical trial readouts, new product launches, and... ► Artikel lesen | |
| NOVONESIS | 54,92 | +0,66 % | Novonesis (Novozymes A/S): Novonesis delivered 8% organic sales growth in the first nine months of 2025 | Novonesis delivered 8% organic sales growth in the first nine months of 2025 and narrowed full-year outlook upwards. COPENHAGEN, Denmark - November 6, 2025. Novonesis delivered 8% organic sales growth... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 8,974 | +3,51 % | Intellia Stock Declines Around 55% in 3 Months: Here's Why | ||
| TEMPUS AI | 58,50 | -2,50 % | TD Cowen Reaffirms Hold Rating on Tempus AI (TEM), Cites the Company's Position to be a Leader | ||
| EDITAS MEDICINE | 1,825 | -1,11 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen |
Das Unternehmen PROKIDNEY CORP kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,060 (-2,48 %) liegt der Kurs bei 2,360 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PROKIDNEY CORP finden Sie auf Wallstreet Online.